5Newburger JW, Takahashi M, Gerber MA, et ol. Diagno-sis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association [J]. Pediatrics,2004,114(6) : 1708-1733.
6Burns JC, Mason WH, Clode MP, et ol. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Muhicenter Kawasaki Disease Study Group [J]. J Pediatr, 1991,118(5) :680-686.
7Ting EC, Capparelli EV, Billman GF, et al. Elevated gamma-glutamyhransferase concentrations in patients with acute Kawasaki disease [J]. J Pediatr Infect Dis,1998, 17(5) :431-432.
8De Maat MP, Bladbjerg EM, Drivsholm T, et al. Inflammation, thrombosis and atherosclerosis: results of the Glostrup study [J]. J Thromb Haemos,2003,1 (5):950- 957.
9Hluboeka Z, Umnerova V, Heller S, et al. Is mild essen- tial hypertension without obvious organ complications and risk factors associated with increased levels of circulating markers of endothelial dysfunction ? Effect of ACE inhibitor therapy [J]. Vnitr Lek,2002,48 (8):718-723 [Czech].
10Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10-to 21-year followup study of 594 patients [J]. Circulation,1996,94(6): 1379-1385.
